Pampa Energia S.A. (ADR) (NYSE:PAM)
On Thursday, Pampa Energia S.A. (ADR) (NYSE:PAM)’s shares inclined 2.95% to $25.11.
PAM has beta value of 1.50. The company has the market capitalization of $1.92 billion. Return on assets ratio of the company was 9.90% while its return on equity ratio was 55.70%. ATR value of company was 1.12 while stock volatility for week was 4.81% while for month was 5.03%. Debt to equity ratio of the company was -1.36 and its current ratio was -0.70.
The mean estimate for the short term price target for Pampa Energia S.A. (ADR) (NYSE:PAM) stands at $25.14 according to 1 Analysts. The higher price target estimate for the stock has been calculated at $25.14. while the lower price target estimate is at $25.14.
Analysts mean recommendation for the stock is 2.00. This number is based on a 1 to 5 scale where 1 indicates a Strong Buy recommendation while 5 represents a Strong Sell.
Pampa Energia S.A. is an integrated electricity company. The Company, through its subsidiaries, is engaged in the generation, transmission and distribution of electricity in Argentina.
Himax Technologies, Inc. (ADR) (NASDAQ:HIMX)
Himax Technologies, Inc. (ADR) (NASDAQ:HIMX)’s shares gained 0.65% to $6.15.
HIMX offered 13.20% EPS for prior five years. The company has 10.40% return on equity value while its ROI ratio was 8.40%. The company has $1.04 billion market capitalizations and the institutional ownership was 19.40%. Its price to book ratio was 2.37. Volatility of the stock was 4.83% for the week while for the month booked as 4.30%.
The mean estimate for the short term price target for Himax Technologies, Inc. (ADR) (NASDAQ:HIMX) stands at $7.74 according to 9 Analysts. The higher price target estimate for the stock has been calculated at $10.00 while the lower price target estimate is at $4.50.
Analysts mean recommendation for the stock is 2.60. This number is based on a 1 to 5 scale where 1 indicates a Strong Buy recommendation while 5 represents a Strong Sell.
Himax Technologies, Inc. is a fabless semiconductor solution provider. The Company is engaged in display driver integrated circuits (IC) and timing controllers used in televisions, laptops, monitors, mobile phones, tablets, digital cameras, car navigation and other consumer electronics devices.
ISIS Pharmaceuticals, Inc. (NASDAQ:ISIS)
At the end of Thursday’s trade, ISIS Pharmaceuticals, Inc. (NASDAQ:ISIS)‘s shares dipped -0.50% to $62.04.
ISIS is currently valued at $7.46 billion. The company has 120.12 million shares outstanding and 90.10% shares of the company were owned by institutional investors. The company has -23.86 value in price to sale ratio while price to book ratio was recorded as -24.72. The company exchanged hands with 1.28 million shares as compared to its average daily volume of 1.97 million shares. It beta stands at 1.76.
The mean estimate for the short term price target for ISIS Pharmaceuticals, Inc. (NASDAQ:ISIS) stands at $65.13 according to 8 Analysts. The higher price target estimate for the stock has been calculated at $88.00 while the lower price target estimate is at $12.00.
Analysts mean recommendation for the stock is 2.80. This number is based on a 1 to 5 scale where 1 indicates a Strong Buy recommendation while 5 represents a Strong Sell.
Isis Pharmaceuticals, Inc. (Isis) is a Ribonucleic acid-targeted (RNA-targeted) drug discovery and development company. The Company is focused to discover and develop antisense drugs. DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.